Document:

Exhibit 10.8

 

INDEMNIFICATION AGREEMENT

 

This Agreement, made
and entered into effective as of the ___ day of _____, 2019 (“Agreement”), by and between Merida Merger Corp. I, a
Delaware corporation (“Company”), and ____________ (“Indemnitee”).

 

WHEREAS, the adoption
of the Sarbanes-Oxley Act of 2002 and other laws, rules and regulations being promulgated have increased the potential for liability
of officers and directors; and

 

WHEREAS, the Board
of Directors of the Company (“Board”) has determined that the ability to attract and retain such persons is in the
best interests of the Company’s shareholders; and

 

WHEREAS, it is reasonable,
prudent and necessary for the Company to obligate itself contractually to indemnify such persons to the fullest extent permitted
by applicable law so that such persons will serve or continue to serve the Company free from undue concern that they will not be
adequately indemnified; and

 

WHEREAS, this Agreement
is a supplement to and in furtherance of Article VII of the Bylaws of the Company, and Article Eighth of the Amended and Restated
Certificate of Incorporation of the Company and any resolutions adopted pursuant thereto and shall neither be deemed to be a substitute
therefor nor to diminish or abrogate any rights of Indemnitee thereunder; and

 

WHEREAS, Indemnitee
is willing to serve on behalf of the Company on the condition that he be indemnified according to the terms of this Agreement;

 

NOW, THEREFORE, in
consideration of the premises and the covenants contained herein, the Company and Indemnitee do hereby covenant and agree as follows:

 

1. Definitions.
For purposes of this Agreement:

 

1.1 “Change
in Control” means a change in control of the Company occurring after the date hereof of a nature that would be required to
be reported in response to Item 6(e) of Schedule 14A of Regulation 14A (or in response to any similar item on any similar schedule
or form) promulgated under the Securities Exchange Act of 1934, as amended (“Act”), whether or not the Company is then
subject to such reporting requirement provided, however, that, without limitation, such a Change in Control shall be deemed to
have occurred if after the date hereof (i) any “person” (as such term is used in Sections 13(d) and 14(d) of the Act),
other than a person who is an officer or director of the Company on the date hereof (and any of such person’s affiliates),
is or becomes “beneficial owner” (as defined in Rule 13d-3 under the Act), directly or indirectly, of securities of
the Company representing 50% or more of the combined voting power of the then outstanding securities of the Company without the
prior approval of at least two-thirds of the members of the Board in office immediately prior to such person attaining such percentage
interest; (ii) the Company is a party to a merger, consolidation, sale of assets or other reorganization, or a proxy contest, as
a consequence of which (A) members of the Board in office immediately prior to such transaction or event constitute less than a
majority of the Board thereafter or (B) the voting securities of the Company outstanding immediately prior to such transaction
do not continue to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity)
more than 50% of the combined voting power of the voting securities of the surviving entity outstanding immediately after such
transaction with the power to elect at least a majority of the board of directors or other governing body of such surviving entity;
or (iii) during any period of two consecutive years, individuals who at the beginning of such period constituted the Board (including
for this purpose any new director whose election or nomination for election by the Company’s shareholders was approved by
a vote of at least two-thirds of the directors then still in office who were directors at the beginning of such period or whose
election or nomination for election was previously so approved) cease for any reason to constitute at least a majority of the Board.

 

     

     

    

 

1.2 “Corporate
Status” means the status of a person who is or was a director, officer, employee, agent or fiduciary of the Company or of
any other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise which such person is or was
serving at the request of the Company. In addition, service at the actual request of the Company, for purposes of this Agreement,
Indemnitee shall be deemed to be serving or to have served at the request of the Company as a director, officer, employee, agent
or fiduciary of any other enterprise if Indemnitee is or was serving as a director, officer, employee, agent or fiduciary of such
enterprise and (A) such enterprise is or at the time of such service was an affiliate of the Company, (B) such enterprise is or
at the time of such service was an employee benefit plan (or related trust) sponsored or maintained by the Company or an affiliate
of the Company or (C) the Company or an affiliate of the Company directly or indirectly caused Indemnitee to be nominated, elected,
appointed, designated, employed, engaged or selected to serve in such capacity

 

1.3 “Disinterested
Director” means a director of the Company who is not and was not a party to the Proceeding in respect of which indemnification
is sought by Indemnitee.

 

1.4 “Expenses”
means all reasonable attorneys’ fees, retainers, court costs (including trial and appeals), transcript costs, fees of experts,
witness fees, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees,
federal, state, local, or foreign taxes imposed as a result of the actual or deemed receipt of any payments under this Agreement,
and all other disbursements or expenses of the types customarily incurred in connection with prosecuting, defending, preparing
to prosecute or defend, appealing, preparing to appeal, investigating, or being or preparing to be a witness in a Proceeding.

 

    2

     

    

 

1.5 “Independent
Counsel” means a law firm, or a member of a law firm, that is experienced in matters of corporation law and neither presently
is, nor in the past five years has been, retained to represent: (i) the Company or Indemnitee in any other matter material to either
such party, or (ii) any other party to the Proceeding giving rise to a claim for indemnification hereunder. Notwithstanding the
foregoing, the term “Independent Counsel” does not include any person who, under the applicable standards of professional
conduct then prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an action to determine
Indemnitee’s rights under this Agreement. Except as provided in the first sentence of Section 9.3 hereof, Independent Counsel
shall be selected by (a) the Disinterested Directors or (b) a committee of the Board consisting of two or more Disinterested Directors
or if (a) and (b) above are not possible, then by a majority of the full Board.

 

1.6 “Proceeding”
means any action, suit, arbitration, alternate dispute resolution mechanism, investigation, administrative hearing or any other
proceeding, , whether conducted by or on behalf of the Company or any other party, whether civil, criminal, administrative or investigative,
except one initiated by an Indemnitee pursuant to Section 11 of this Agreement to enforce his rights under this Agreement.

 

2. Services
by Indemnitee.

 

Indemnitee agrees to
serve as a director, officer or employee of the Company. Indemnitee may at any time and for any reason resign from such position
(subject to any other contractual obligation or any obligation imposed by operation of law).

 

3. Indemnification
- General.

 

The Company shall indemnify,
and, subject to Section 26 hereof, advance Expenses to, Indemnitee as provided in this Agreement to the fullest extent permitted
by applicable law in effect on the date hereof and to such greater extent as any amendment to or interpretation of applicable law
may thereafter from time to time permit. The rights of Indemnitee provided under the preceding sentence shall include, but shall
not be limited to, the rights set forth in the other Sections of this Agreement.

 

4. Proceedings
Other Than Proceedings by or in the Right of the Company.

 

Indemnitee shall be
entitled to the rights of indemnification provided in this Agreement if, by reason of his Corporate Status, he is, was or is threatened
to be made, a party to any threatened, pending or completed Proceeding, other than a Proceeding by or in the right of the Company.
Pursuant to this Agreement, subject to Section 26 hereof, Indemnitee shall be indemnified against Expenses, judgments, penalties,
fines and amounts paid in settlement actually and reasonably incurred by him or on his behalf in connection with any such Proceeding
or any claim, issue or matter therein, if he acted in good faith and in a manner he reasonably believed to be in or not opposed
to the best interests of the Company, and, with respect to any criminal Proceeding, had no reasonable cause to believe his conduct
was unlawful.

 

    3

     

    

 

5. Proceedings
by or in the Right of the Company.

 

Indemnitee shall be
entitled to the rights of indemnification provided in this Agreement if, by reason of his Corporate Status, he was or is threatened
to be made, a party to any threatened, pending or completed Proceeding brought by or in the right of the Company to procure a judgment
in its favor. Pursuant to this Agreement, subject to Section 26 hereof, Indemnitee shall be indemnified against amounts paid in
settlement and Expenses actually and reasonably incurred by him or on his behalf in connection with the defense or settlement of
any such Proceeding if he acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests
of the Company. Notwithstanding the foregoing, no indemnification under this paragraph shall be made in respect of (1) a threatened
or pending Proceeding which is settled or otherwise disposed of, or (2) any claim, issue or matter as to which such person shall
have been adjudged to be liable to the Company, unless and only to the extent that the court in which such Proceeding shall have
been brought, was brought or is pending, shall determine, upon application, that Indemnitee is fairly and reasonably entitled to
indemnity for such portion of the settlement amount and Expenses as the court deems proper.

 

6. Indemnification
for Expenses of Party Who is Wholly or Partly Successful.

 

Notwithstanding any
other provision of this Agreement except for Section 26 hereof, to the extent that Indemnitee is, by reason of his Corporate Status,
a party to and is successful, on the merits or otherwise, in any Proceeding, he shall be indemnified against all Expenses (and,
when eligible hereunder, amounts paid in settlement) actually and reasonably incurred by him or on his behalf in connection therewith.
If Indemnitee is not wholly successful in such Proceeding but is successful, on the merits or otherwise, as to one or more but
less than all claims, issues or matters in such Proceeding, the Company shall indemnify Indemnitee against all Expenses (and, when
eligible hereunder, amount paid in settlement) actually and reasonably incurred by him or on his behalf in connection with each
successfully resolved claim, issue or matter. For purposes of this Agreement, the term “successful, on the merits or otherwise,”
includes, but is not limited to, (i) any termination, withdrawal, or dismissal (with or without prejudice) of any Proceeding against
the Indemnitee without any express finding of liability or guilt against him, and (ii) the expiration of 90 days after the making
of any claim or threat of a Proceeding without the institution of the same and without any promise or payment made to induce a
settlement.

 

7. Indemnification
for Expenses as a Witness.

 

Notwithstanding any
other provision of this Agreement except for Section 26 hereof, to the extent that Indemnitee is, by reason of his Corporate Status,
a witness in any Proceeding, he shall be indemnified against all Expenses actually and reasonably incurred by him or on his behalf
in connection therewith.

 

    4

     

    

 

8. Advancement
of Expenses and Other Amounts.

 

Subject to Section
26 hereof, the Company shall advance all Expenses, judgments, penalties, fines and, when eligible hereunder, amounts paid in settlement,
incurred by or on behalf of Indemnitee in connection with any Proceeding within thirty (30) days after the receipt by the Company
of a statement or statements from Indemnitee requesting such advance or advances from time to time, whether prior to or after final
disposition of such Proceeding. Such statement or statements shall reasonably evidence the Expenses, judgments, penalties, fines
and amounts paid in settlement, incurred by Indemnitee and shall include or be preceded or accompanied by an agreement by or on
behalf of Indemnitee to repay any Expenses, judgments, penalties, fines and amounts paid in settlement advanced if it shall ultimately
be determined that Indemnitee is not entitled to be indemnified against such Expenses, judgments, penalties, fines and, when eligible
hereunder, amounts paid in settlement. In connection with any request for advancement of Expenses, judgments, penalties, fines
and amounts paid in settlement, Indemnitee shall not be required to provide any documentation or information to the extent that
the provision thereof would undermine or otherwise jeopardize attorney-client privilege. The Company’s obligation in respect
of the advancement of Expenses, judgments, penalties, fines and amounts paid in settlement in connection with a criminal Proceeding
in which Indemnitee is a defendant shall terminate at such time as Indemnitee pleads guilty or is convicted after trial and such
conviction becomes final and no longer subject to appeal. Advances shall be unsecured and interest free. Advances shall be made
without regard to Indemnitee’s ability to repay such amounts and without regard to Indemnitee’s ultimate entitlement
to indemnification under the other provisions of this Agreement.

 

9. Procedure
for Determination of Entitlement to Indemnification.

 

9.1 To
obtain indemnification under this Agreement in connection with any Proceeding, and for the duration thereof, Indemnitee shall submit
to the Company a written request, including therein or therewith such documentation and information as is reasonably available
to Indemnitee and is reasonably necessary to determine whether and to what extent Indemnitee is entitled to indemnification. The
Secretary of the Company shall, promptly upon receipt of any such request for indemnification, advise the Board in writing that
Indemnitee has requested indemnification.

 

9.2 Upon
written request by Indemnitee for indemnification pursuant to Section 9.1 hereof, a determination, if required by applicable law,
with respect to Indemnitee’s entitlement thereto shall be made in such case: (i) if a Change in Control shall have occurred,
by Independent Counsel (unless Indemnitee shall request that such determination be made by the Board or the shareholders, in which
case in the manner provided for in clauses (ii) or (iii) of this Section 9.2) in a written opinion to the Board, a copy of which
shall be delivered to Indemnitee; (ii) if a Change of Control shall not have occurred, at the election of the Company, (A) by the
Board by a majority vote of a quorum consisting of Disinterested Directors, or (B) if a quorum of the Board consisting of Disinterested
Directors is not obtainable, by a majority of a committee of the Board consisting of two or more Disinterested Directors, or (C)
by Independent Counsel in a written opinion to the Board, a copy of which shall be delivered to Indemnitee, or (D) by the shareholders
of the Company, by a majority vote of a quorum consisting of shareholders who are not parties to the proceeding, or if no such
quorum is obtainable, by a majority vote of shareholders who are not parties to such proceeding; or (iii) as provided in Section
10.2 of this Agreement. If it is so determined that Indemnitee is entitled to indemnification, payment to Indemnitee shall be made
within ten (10) days after such determination. Indemnitee shall cooperate with the person, persons or entity making such determination
with respect to Indemnitee’s entitlement to indemnification, including providing to such person, persons or entity upon reasonable
advance request any documentation or information which is not privileged or otherwise protected from disclosure and which is reasonably
available to Indemnitee and reasonably necessary to such determination. Any costs or expenses (including attorneys’ fees
and disbursements) incurred by Indemnitee in so cooperating with the person, persons or entity making such determination shall
be borne by the Company (irrespective of the determination as to Indemnitee’s entitlement to indemnification) and the Company
hereby indemnifies and agrees to hold Indemnitee harmless therefrom.

 

    5

     

    

 

9.3 If
a Change of Control shall have occurred, Independent Counsel shall be selected by Indemnitee (unless Indemnitee shall request that
such selection be made by the Board), and Indemnitee (or the Board, as the case may be) shall give written notice to the other
party advising it of the identity of Independent Counsel so selected. In either event, Indemnitee or the Company, as the case may
be, may, within seven days after such written notice of selection shall have been given, deliver to the Company or to Indemnitee,
as the case may be, a written objection to such selection. Such objection may be asserted only on the ground that Independent Counsel
so selected does not meet the requirements of “Independent Counsel” as defined in Section 1 of this Agreement, and
the objection shall set forth with particularity the factual basis of such assertion. If such written objection is made, Independent
Counsel so selected may not serve as Independent Counsel unless and until a court has determined that such objection is without
merit. If, within 20 days after submission by Indemnitee of a written request for indemnification pursuant to Section 9.1 hereof,
no Independent Counsel shall have been selected and not objected to, either the Company or Indemnitee may petition a court of competent
jurisdiction, for resolution of any objection which shall have been made by the Company or Indemnitee to the other’s selection
of Independent Counsel and/or for the appointment as Independent Counsel of a person selected by such court or by such other person
as such court shall designate, and the person with respect to whom an objection is so resolved or the person so appointed shall
act as Independent Counsel under Section 9.2 hereof. The Company shall pay any and all reasonable fees and expenses of Independent
Counsel incurred by such Independent Counsel in connection with its actions pursuant to this Agreement, and the Company shall pay
all reasonable fees and expenses incident to the procedures of this Section 9.3, regardless of the manner in which such Independent
Counsel was selected or appointed. Upon the due commencement date of any judicial proceeding pursuant to Section 11.1(iii) of this
Agreement, Independent Counsel shall be discharged and relieved of any further responsibility in such capacity (subject to the
applicable standards of professional conduct then prevailing).

 

    6

     

    

 

10. Presumptions
and Effects of Certain Proceedings.

 

10.1 In
making a determination with respect to entitlement to indemnification hereunder, the person or persons or entity making such determination
shall presume that Indemnitee is entitled to indemnification under this Agreement if Indemnitee has submitted a request for indemnification
in accordance with Section 9.1 of this Agreement, and the Company shall have the burden of proof to overcome that presumption by
clear and convincing evidence in connection with the making by any person, persons or entity of any determination contrary to that
presumption.

 

10.2 If
the person, persons or entity empowered or selected under Section 9 of this Agreement to determine whether Indemnitee is entitled
to indemnification shall not have made a determination within sixty (60) days after receipt by the Company of the request therefor,
the requisite determination of entitlement to indemnification shall be deemed to have been made and Indemnitee shall be entitled
to such indemnification, absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary
to make Indemnitee’s statement not materially misleading, in connection with the request for indemnification, or (ii) prohibition
of such indemnification under applicable law; provided, however, that such 60-day period may be extended for a reasonable time,
not to exceed an additional thirty (30) days, if the person, persons or entity making the determination with respect to entitlement
to indemnification in good faith require(s) such additional time for the obtaining or evaluating of documentation and/or information
relating thereto; and provided, further, however, that the foregoing provisions of this Section 10.2 shall not apply (i) if the
determination of entitlement to indemnification is to be made by the shareholders pursuant to Section 9.2 of this Agreement and
if (A) within 15 days after receipt by the Company of the request for such determination the Board has resolved to submit such
determination to the shareholders for their consideration at an annual meeting thereof to be held within 75 days after such receipt
and such determination is made thereat, or (B) a special meeting of shareholders is called within 15 days after such receipt for
the purpose of making such determination, such meeting is held for such purpose within 60 days after having been so called and
such determination is made thereat, or (ii) if the determination of entitlement to indemnification is to be made by Independent
Counsel pursuant to Section 9.2 of this Agreement. In connection with each meeting at which a shareholder determination will be
made, the Company shall solicit proxies that expressly include a proposal to indemnify or reimburse the Indemnitee. The Company
shall afford the Indemnitee ample opportunity to present evidence of the facts upon which the Indemnitee relies for indemnification
in any Company proxy statement relating to such shareholder determination. Subject to the fiduciary duties of its members under
applicable law, the Board will not recommend against indemnification or reimbursement in any proxy statement relating to the proposal
to indemnify or reimburse the Indemnitee.

 

10.3 The
termination of any Proceeding or of any claim, issue or matter therein, by judgment, order, settlement or conviction, or upon a
plea of nolo contendere or its equivalent, shall not (except as otherwise expressly provided in this Agreement) of itself adversely
affect the right of Indemnitee to indemnification or create a presumption that Indemnitee did not act in good faith and in a manner
which he reasonably believed to be in or not opposed to the best interests of the Company or, with respect to any criminal Proceeding,
that Indemnitee had reasonable cause to believe that his conduct was unlawful.

 

    7

     

    

 

10.4 Reliance
as Safe Harbor.

 

For purposes of this
Agreement, the Indemnitee shall be deemed to have acted in good faith and in a manner he reasonably believed to be in or not opposed
to the best interests of the Company, or, with respect to any criminal Proceeding, to have had no reasonable cause to believe his
conduct was unlawful, if his action is based on (i) the records or books of account of the Company, or another enterprise, including
financial statements, (ii) information supplied to him by the officers of the Company or another enterprise in the course of their
duties, (iii) the advice of legal counsel for the Company or another enterprise, or of an independent certified public accountant
or an appraiser or other expert selected with reasonable care by the Company or another enterprise. The term “another enterprise”
as used in this Section shall mean any other corporation or any partnership, joint venture, trust, employee benefit plan or other
enterprise of which the Indemnitee is or was serving at the request of the Company as a director, officer, partner, trustee, employee
or agent. The provisions of this Section shall not be deemed to be exclusive or to limit in any way the other circumstances in
which the Indemnitee may be deemed to have met the applicable standard of conduct set forth herein. Whether or not the foregoing
provisions of this Section 10.4 are satisfied, it shall in any event be presumed that Indemnitee has at all times acted in good
faith and in a manner he reasonably believed to be in or not opposed to the best interests of the Company, or, with respect to
any criminal Proceeding, to have had no reasonable cause to believe Indemnitee’s conduct was unlawful. Anyone seeking to
overcome this presumption shall have the burden of proof and the burden of persuasion by clear and convincing evidence.

 

11. Remedies
of Indemnitee.

 

11.1 In
the event that (i) a determination is made pursuant to Section 9 of this Agreement that Indemnitee is not entitled to indemnification
under this Agreement, (ii) advancement of Expenses is not timely made pursuant to Section 8 of this Agreement, (iii) the determination
of indemnification is to be made by Independent Counsel pursuant to Section 9.2 of this Agreement and such determination shall
not have been made and delivered in a written opinion within sixty (60) days after receipt by the Company of the request for indemnification,
(iv) payment of indemnification is not made pursuant to Section 7 of this Agreement within thirty (30) days after receipt by the
Company of a written request therefor, or (v) payment of indemnification is not made within thirty (30) days after a determination
has been made that Indemnitee is entitled to indemnification or such determination is deemed to have been made pursuant to Section
9 or 10 of this Agreement, Indemnitee shall be entitled to an adjudication in an appropriate court of the State of New York, or
in any other court of competent jurisdiction, of his entitlement to such indemnification or advancement of Expenses, judgments,
penalties, fines or, when eligible hereunder, amounts paid in settlement. The Company shall not oppose Indemnitee’s right
to seek any such adjudication.

 

    8

     

    

 

11.2 In
the event that a determination shall have been made pursuant to Section 9 of this Agreement that Indemnitee is not entitled to
indemnification, any judicial proceeding commenced pursuant to this Section shall be conducted in all respects as a de novo trial
on the merits and Indemnitee shall not be prejudiced by reason of that adverse determination.

 

11.3 If
a determination shall have been made or deemed to have been made pursuant to Section 9 or 10 of this Agreement that Indemnitee
is entitled to indemnification, the Company shall be bound by such determination in any judicial proceeding commenced pursuant
to this Section, absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make
Indemnitee’s statement not materially misleading, in connection with the request for indemnification, or (ii) prohibition
of such indemnification under applicable law.

 

11.4 The
Company shall be precluded from asserting in any judicial proceeding commenced pursuant to this Section that the procedures and
presumptions of this Agreement are not valid, binding and enforceable and shall stipulate in any such court that the Company is
bound by all the provisions of this Agreement.

 

11.5 In
the event that Indemnitee, pursuant to this Section, seeks a judicial adjudication of his rights under, or to recover damages for
breach of, this Agreement or any other agreement, including any other indemnification, contribution or advancement agreement, or
any provision of the certificate of incorporation or by-laws of the Company now or hereafter in effect, or for recovery under directors’
and officers’ liability insurance policies maintained by the Company, Indemnitee shall be entitled to recover from the Company,
and shall be indemnified by the Company against, any and all expenses (of the kinds described in the definition of Expenses) actually
and reasonably incurred by him in such judicial adjudication, but only if he prevails therein. If it shall be determined in such
judicial adjudication that Indemnitee is entitled to receive less than all of the indemnification or advancement of expenses sought,
the expenses incurred by Indemnitee in connection with such judicial adjudication shall be appropriately prorated. In addition,
the Company shall, if so requested by Indemnitee, advance the foregoing expenses to Indemnitee, subject to and in accordance with
Section 8.

 

    9

     

    

 

12. Procedure
Regarding Indemnification.

 

With respect to any
Proceedings, the Indemnitee, prior to taking any action with respect to such Proceeding, shall consult with the Company as to the
procedure to be followed in defending, settling, or compromising the Proceeding and may not consent to any settlement or compromise
of the Proceeding without the written consent of the Company (which consent may not be unreasonably withheld or delayed). The Company
shall be entitled to participate in defending, settling or compromising any Proceeding and to assume the defense of such Proceeding
with counsel of its choice and shall assume such defense if requested by the Indemnitee. Notwithstanding the election by, or obligation
of, the Company to assume the defense of a Proceeding, the Indemnitee shall have the right to participate in the defense of such
Proceeding and to employ counsel of Indemnitee’s choice, but the fees and expenses of such counsel shall be at the expense of the
Indemnitee unless (i) the employment of such counsel has been authorized in writing by the Company, or (ii) the Indemnitee has
reasonably concluded that there may be defenses available to him which are different from or additional to those available to the
Company (in which latter case the Company shall not have the right to direct the defense of such Proceeding on behalf of the Indemnitee),
in either of which events the fees and expenses of not more than one additional firm of attorneys selected by the Indemnitee shall
be borne by the Company. If the Company assumes the defense of a Proceeding, then counsel for the Company and Indemnitee shall
keep Indemnitee reasonably informed of the status of the Proceeding and promptly send to Indemnitee copies of all documents filed
or produced in the Proceeding, and the Company shall not compromise or settle any such Proceeding without the written consent of
the Indemnitee (which consent may not be unreasonably withheld or delayed) if the relief provided shall be other than monetary
damages and shall promptly notify the Indemnitee of any settlement and the amount thereof.

 

		13.	Non-Exclusivity; Survival of Rights; Insurance; Subrogation; Contribution.

 

13.1 The
rights of indemnification and to receive advancement of Expenses as provided by this Agreement shall not be deemed exclusive of
any other rights to which Indemnitee may at any time be entitled under applicable law, the certificate of incorporation or by-laws
of the Company, any agreement, a vote of shareholders or a resolution of directors, or otherwise. No amendment, alteration or repeal
of this Agreement or any provision hereof shall be effective as to any Indemnitee with respect to any action taken or omitted by
such Indemnitee in his Corporate Status prior to such amendment, alteration or repeal.

 

13.2 To
the extent that the Company maintains an insurance policy or policies providing liability insurance for directors, officers, employees,
agents or fiduciaries of the Company or of any other corporation, partnership, joint venture, trust, employee benefit plan or other
enterprise which such person serves at the request of the Company, Indemnitee shall be covered by such policy or policies in accordance
with its or their terms to the maximum extent of the coverage available for any such director, officer, employee, agent or fiduciary
under such policy or policies.

 

13.3 In
the event of any payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights
of recovery of Indemnitee, who shall execute all papers required and take all action necessary to secure such rights, including
execution of such documents as are reasonably necessary to enable the Company to bring suit to enforce such rights.

 

13.4 The
Company shall not be liable under this Agreement to make any payment of amounts otherwise indemnifiable hereunder if and to the
extent that Indemnitee has otherwise actually received such payment under any insurance policy, contract, agreement or otherwise.

 

    10

     

    

 

13.5 If
a determination is made that Indemnitee is not entitled to indemnification, after Indemnitee submits a written request therefor,
under this Agreement, then in respect of any threatened, pending or completed Proceeding in which the Company is jointly liability
with the Indemnitee (or would be if joined in such Proceeding), the Company shall contribute to the amount of Expenses, judgments,
fines and amounts paid in settlement by the Indemnitee in such proportion as is appropriate to reflect (i) the relative benefits
received by the Company on the one hand and the Indemnitee on the other hand from the transaction from which Proceeding arose,
and (ii) the relative fault of the Company on the one hand and of the Indemnitee on the other hand in connection with the events
that resulted in such Expenses, judgments, fines or amounts paid in settlement, as well as any other relevant equitable considerations.
The relative fault of the Company on the one hand and of the Indemnitee on the other hand shall be determined by reference to,
among other things, the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent
the circumstances resulting in such Expenses, judgments, fines or amounts paid in settlement. The Company agrees that it would
not be just and equitable if contribution pursuant to this Section were determined by pro rata allocation or any other method of
allocation that does not take into account the foregoing equitable considerations. The determination as to the amount of the contribution,
if any, shall be made by: (i) a court of competent jurisdiction upon the application of both the Indemnitee and the Company (if
the Proceeding had been brought in, and final determination had been rendered by such court); (ii) the Board by a majority vote
of a quorum consisting of Disinterested Directors; or (iii) Independent Counsel, if a quorum is not obtainable for purpose of (ii)
above, or, even if obtainable, a quorum of Disinterested Directors so directs.

 

14. Duration
of Agreement.

 

This Agreement shall
continue until and terminate upon the later of: (a) ten (10) years after the date that Indemnitee shall have ceased to serve as
a director and/or officer of the Company, or (b) the final termination of all pending Proceedings in respect of which Indemnitee
is granted rights of indemnification or advancement of Expenses, judgments, penalties, fines or amounts paid in settlement hereunder
and or any proceeding commenced by Indemnitee pursuant to Section 11 of this Agreement. This Agreement shall be binding upon the
Company and its successors and assigns and shall inure to the benefit of Indemnitee and his spouse, heirs, executors, personal
representatives and administrators. The Company shall require and cause any successor (whether direct or indirect by purchase,
merger, consolidation, or otherwise) to all, substantially all, or a substantial part, of the business and/or assets of the Company,
by written agreement in form and substance satisfactory to Indemnitee, expressly to assume and agree to perform this Agreement
in the same manner and to the same extent that the Company would be required to perform if no such succession had taken place.

 

    11

     

    

 

15. Severability.

 

If any provision or
provisions of this Agreement shall be held to be invalid, illegal or unenforceable for any reason whatsoever: (a) the validity,
legality and enforceability of the remaining provisions of this Agreement (including, without limitation, each portion of any Section
of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal
or unenforceable) shall not in any way be affected or impaired thereby; and (b) to the fullest extent possible, the provisions
of this Agreement (including, without limitation, each portion of any Section of this Agreement containing any such provision held
to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall be construed so as to give
effect to the intent manifested by the provision held invalid, illegal or unenforceable.

 

16. Entire
Agreement.

 

This Agreement constitutes
the entire agreement between the Company and the Indemnitee with respect to the subject matter hereof and supersedes all prior
agreements, understanding, negotiations and discussion, both written and oral, between the parties hereto with respect to such
subject matter (the “Prior Agreements”); provided, however, that if this Agreement shall ever be held void or unenforceable
for any reasons whatsoever, and is not reformed pursuant to Section 15 hereof, then (i) this Agreement shall not be deemed to have
superseded any Prior Agreements; (ii) all of such Prior Agreements shall be deemed to be in full force and effect notwithstanding
the execution of this Agreement; and (iii) the Indemnitee shall be entitled to maximum indemnification benefits provided under
any Prior Agreements, as well as those provided under applicable law, the certificate of incorporation or by-laws of the Company,
a vote of shareholders or resolution of directors.

 

17. Exception
to Right of Indemnification or Advancement of Expenses.

 

17.1 Except
as provided in Section 11.5, Indemnitee shall not be entitled to indemnification or advancement of Expenses, judgments, penalties,
fines and amounts paid in settlement under this Agreement with respect to any Proceeding, or any claim therein, brought or made
by him against the Company.

 

17.2 Indemnitee
shall not be entitled to indemnification or advancement of Expenses under this Agreement with respect to any Proceeding, or any
claim therein, arising from the purchase and sale by Indemnitee of securities in violation of Section 16(b) of the Exchange Act
or Company similar successor statute.

 

18. Covenant
Not to Sue; Limitation of Actions; Release of Claims.

 

No legal action shall
be brought and no cause of action shall be asserted by or on behalf of the Company (or any of its subsidiaries) against the Indemnitee,
his spouse, heirs, executors, personal representatives or administrators after the expiration of two (2) years from the date of
accrual of such cause of action and any claim or cause of action of the Company (or any of its subsidiaries) shall be extinguished
and deemed released unless asserted by the filing of a legal action within such two (2) year period; provided, however, that if
any shorter period of limitation is otherwise applicable to any such cause of action, such shorter period shall govern.

 

    12

     

    

 

19. Identical
Counterparts.

 

This Agreement may
be executed in one or more counterparts, each of which shall for all purposes be deemed to be an original but all of which together
shall constitute one and the same Agreement.

 

20. Headings.

 

The headings of the
paragraphs of this Agreement are inserted for convenience only and shall not be deemed to constitute part of this Agreement or
to affect the construction thereof.

 

21. Modification
and Waiver.

 

No supplement, modification
or amendment of this Agreement shall be binding unless executed in writing by both of the parties hereto. No waiver of any of the
provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions hereof (whether or not similar)
nor shall such waiver constitute a continuing waiver.

 

22. Notice
by Indemnitee.

 

Indemnitee agrees promptly
to notify the Company in writing upon being served with any summons, citation, subpoena, complaint, indictment, information or
other document relating any Proceeding or matter which may be subject to indemnification or advancement of Expenses, judgments,
penalties, fines or amounts paid in settlement covered hereunder. The failure to notify the Company on a timely basis shall not
constitute a waiver of Indemnitee’s rights under this Agreement, except to the extent that such failure or delay (i) causes
the amounts paid or to be paid by the Company to be greater than they otherwise would have been, (ii) adversely affects the Company’s
ability to obtain for itself or Indemnitee coverage or proceeds under any insurance policy available to the Company or Indemnitee,
or (iii) otherwise results in prejudice to the Company.

 

    13

     

    

 

23. Notices.

 

All notices, requests,
demands and other communications hereunder shall be in writing and shall be deemed to have been duly given if (i) delivered by
hand and receipted for by the party to whom such notice or other communication shall have been directed, or (ii) mailed by certified
or registered mail with postage prepaid, on the third business day after the date on which it is so mailed:

 

If to Indemnitee, to:

 

If to the Company, to:

 

Merida Merger Corp. I

641 Lexington Avenue, 18th Floor

New York, NY 10022

 

or to such other address or such other
person as Indemnitee or the Company shall designate in writing in accordance with this Section, except that notices regarding changes
in notices shall be effective only upon receipt.

 

24. Governing
Law.

 

The parties agree that
this Agreement shall be governed by, and construed and enforced in accordance with, the laws of the State of New York applicable
to contracts made and performed in that state without giving effect to the principles of conflicts of laws. The Company and Indemnitee
each hereby irrevocably consents to the jurisdiction of the courts of the State of New York and the federal courts within the State
for all purposes in connection with any action or proceeding that arises out of or relates to this Agreement and agrees that any
action instituted under this Agreement shall be brought only in the United States District Court for the Southern District of New
York and any New York State court within that District.

 

25. Mutual
Acknowledgment.

 

Both the Company and
Indemnitee acknowledge that, in certain instances, Federal law or applicable public policy may prohibit the Company from indemnifying
its directors and officers under this Agreement or otherwise. Indemnitee understands and acknowledges that the Company has undertaken
or may be required in the future in certain circumstances to undertake with the Securities and Exchange Commission to submit the
question of indemnification to a court for a determination of the Company’s right under public policy to indemnify Indemnitee.

 

26. Waiver
of Claims to Trust Account.

 

Indemnitee hereby agrees
that it does not have any right, title, interest or claim of any kind (each, a “Claim”) in or to any monies in the
trust account established in connection with the Company’s initial public offering for the benefit of the Company and holders
of shares issued in such offering, and hereby waives any Claim it may have in the future as a result of, or arising out of, any
services provided to the Company and will not seek recourse against such trust account for any reason whatsoever.

 

    14

     

    

 

27. Miscellaneous.

 

Use of the masculine
pronoun shall be deemed to include usage of the feminine pronoun where appropriate.

 

IN WITNESS WHEREOF,
the parties hereto have executed this Agreement on the day and year first above written.

 

	 	MERIDA MERGER CORP. I
	 	 
	 	By:	 
	 	 	Name:	     
	 	 	Title:	 
	 	 
	 	INDEMNITEE
	 	 
	 	 

 

 

15EX-4.12

 Exhibit 4.12 

INVESTIGATOR INITIATED CLINICAL TRIAL AGREEMENT 

This Investigator Initiated Clinical Trial Agreement (“Agreement”) is made as of the _I7* day of October. 20LS (“Effective
Date”) between Kazia Therapeutics Ltd (ACN 063 259 754) a company incorporated in Australia with a principal place of business at 1.24, 300 Barangaroo Avenue, Sydney, NSW 2000, Australia (“Company”), and Dana-Farber/Partners Cancer
Care, Inc., a collaboration among Dana-Farber Cancer Institute, The Brigham and Women’s Hospital, Inc. and The General Hospital Corporation, d/b/a Massachusetts General Hospital, a
not-for-profit tax-exempt corporation organized under the laws of the Commonwealth of Massachusetts with its principal place of
business at 44 Binney Street, Boston, MA 02115 (“Institution”) each referred to herein individually as a “Party” and collectively as the “Parties”. 

The Parties to this Agreement share a common mission of improving the public health by engaging in research for the purpose of discovering and
making available to the public new and improved medical drugs, devices, procedures, and information. In connection with this mission. Company desires to have further clinical research conducted on its Drug described below. Institution, through
.1. Pablo Leone, M.I). (“Principal Investigator”), having particular expertise and opportunity, desires to provide this research. 

Accordingly, for good and valuable consideration, the sufficiency of which is hereby acknowledged, the Parties agree as follows: 

Section I: Study Performance 
 I.
I    Conduct of Study in Accordance with Protocol: Priority of Terms. Subject to the initial and continuing approvals described in Section 1.2 below. Institution, through Principal Investigator, agrees to conduct a
clinical study of GDC-0084 (“Study Drug”) in accordance with the study protocol entitled “Phase II Trial of GDC-0084 in combination with
Trastuzumab for Patients with HER2-Positive Breast Cancer Brain Metastases,” attached to this Agreement as Exhibit A and herein incorporated by reference (“Study”). The Parties to this agree that the Study will be performed in
strict accordance with the Study protocol entitled above, and any subsequent amendments thereto (the “Protocol”), applicable federal, state, and local laws, regulations and guidelines, and good clinical practices as required under FDA
regulations (“GCPs”). In the event of any conflict between the Protocol and the provisions of the main body of this Agreement, the Protocol shall govern with respect to scientific. Study management and reporting and subject consent issues,
and the provisions of the main body of this Agreement shall govern with respect to all other issues. 
 1.2    Study Review and
Approvals. The Study shall be conducted by personnel, agents, vendors, or consultants of Institution under the direction of the Principal Investigator at Institution or additional facilities with the prior approval and ongoing review of all
appropriate and necessary review authorities. Institution, through Principal Investigator, shall provide Company with written evidence of review and approval of this Study by Institution’s Institutional Review Board (“IRB”) prior to
the initiation of the Study and shall inform Company olThc IRB’s continuing reviews of the Study promptly after each such review takes place, which shall be at least once per year. Initiation of the Study Protocol shall not begin until IRB
approval is obtained. Institution may make any material amendment(s) to the informed consent form if Institution is so expressly Clinical Trial Agreement directed by Institution’s IRB. A “material amendment” is any amendment to
conform to Institution’s obligations under 45 CFR Pt. 46.116 (a) (2) and 21 CFR Pt. 50.25. In accordance with the obligations under the Food and Drug Administration Amendment Act of 2007 (“the ACT”), Institution agrees to
register this clinical trial with the public registry clinicaltrials.gov before enrollment of the first patient at Institution and comply with all of the Acts requirements thereafter. Additionally, Institution will be exclusively responsible for
updating and/or amending such registration as appropriate. Institution is responsible for IND submission. Company will provide to Institution a Letter of Authorization (LoA) to cross-reference the Company
GDC-0084 IND and Company requests the opportunity to review the Institution IND prior to FDA submission. 

 1.3    Completion of the Study. For purposes of this Agreement,
Company and Institution shall consider the Study to be complete and concluded at all sites at such time as achievement of the primary endpoint is reached or as otherwise specified in the Protocol (“Study Conclusion”). 

1.4    Provision and Use of Study Drug. Company shall be responsible for providing and delivering to the research
pharmacy of each site of Institution, at no charge, sufficient quantities of the Study Drug (GDC-0084 15mg Capsules, bottled and identified with lot number) as may be required for the Study in accordance with
the Study schedule. Institution, through Principal Investigator, will safeguard such Study Drug with the degree of care used for its own property and shall return or otherwise dispose of any remaining Study Drug at the Study Conclusion in accordance
with Company’s instructions and Institution’s pharmacy’s Standard Operating Procedures (SOP’s) for drug destruction. Institution and Principal Investigator shall not use any Study Drug for any purpose other than the Study, unless
otherwise agreed. Company represents and warrants that it is in compliance with federal, state, and local laws and regulations relating to the manufacture and formulation of any investigational drug and to any other materials supplied, and with all
applicable legal requirements. Responsibilities between the Parties are provided in Exhibit x 
 Section 2: Data and Safety Monitoring Plan and
Reports; Material Subject Information 
 Company agrees to notify Principal Investigator in writing promptly (no later than 30 days) of
information (such as Study Drug results or findings from other studies involving Study Drug), including results obtained for a period of two (2) years after completion or closure of the Study that could affect the safety or medical care of
subjects who were at any point enrolled in the Study, influence the conduct of the Study, or alter the IRB’s approval. Company and Institution shall comply with, and nothing herein shall limit, their respective reporting requirements to
regulatory authorities, including, for example, the Food and Drug Administration, the Office for Human Research Protections, and others as required. Institution, through the Principal Investigator and/or IRB as appropriate, shall be responsible for
informing subjects of the above important information they learn from Company in accordance with the IRB-approved informed consent form and Company shall not contact them. No other provision of this Agreement
shall be construed to override the provisions of this Section 2. 
 In addition, Institution shall notify Company of any suspected
unexpected serious adverse reactions (“SUSARs”) during the course of the Study within 24 hours of Institution receiving notification of their occurrence, so that Company may fulfil its regulatory reporting requirements. Institution shall
reasonably support any necessary follow-up of SUSARs. In addition, Institution shall provide quarterly safety listings to Company, in a format mutually acceptable, for inclusion in its mandatory regulatory
filings. 

 Section 3: Study Data/Results 

3.1    Provision of Data/Results. 

(a)    A Clinical Study Report will be supplied to Company by Institution at the conclusion of the Study. Company shall
have the right to use data produced in the performance of the Study (“Data”) for all lawful purposes in accordance with Section 3.2. If Company requests, full access to the case report forms and underlying data for the purpose of
making any submission to the Food and Drug Administration and other foreign health authorities, Institution and Company shall arrange for further transfer at Company’s expense. If Company wishes to file the Study Data with the FDA or other
health authority at some time in the future, Institution agrees to provide reasonable assistance to Company for such activities, including responding to questions about the Study Data and Company and Institution shall negotiate a budget for payments
to support the work necessary for Institution to provide the requested assistance/information to Company. Company acknowledges and agrees that in no event is Institution responsible for formatting or
re-formatting the Data so as to be acceptable for submission to the FDA or other regulatory agencies, unless separately negotiated and agreed between Company and Institution. 

(b)    Institution shall own the data from its Study, its medical records and Institution- issued research notebooks. 

3.2    Use of Data/Results. Institution shall comply in all material respects with all applicable federal, state
and local laws and regulations regarding the privacy of individually identifiable health information (including its collection, use, storage, and disclosure), including, but not limited to Health Insurance Portability and Accountability Act of 1996
(“HIPAA) and the regulations promulgated thereunder, as may be amended from time to time. Company may receive individually identifiable health information subject data regarding serious adverse events and patient’s response to therapy.
Therefore, Company agrees to use and disclose individually identifiable health information only in a manner consistent with applicable federal, state and local laws and regulations regarding the privacy of individually identifiable health
information, including, but not limited to the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) and the regulations promulgated thereunder, as may be amended from time to time and any applicable subject authorization,
including the terms and conditions of the informed consent executed by the patient, or as otherwise may be required by applicable law. Company may use information that is not identifiable under any applicable U.S. laws for any research and
development purpose. Company will use all reasonable efforts to protect the privacy and security of individually identifiable health information and will require its business partners to do so also. Company will not contact any Study subjects,
unless permitted by the informed consent form. The Parties to this Agreement agree that all protections, ownership rights and use restrictions afforded by this Agreement to the health information and data of research subjects enrolled, in the Study
will apply equally to any health information or other data collected from such research subjects’ pregnant partners, if any and regardless of when during the Study the partner becomes pregnant, whether or not a pregnant partner is formally
recognized by the IRB as being a human research subject enrolled in the Study. No other provision in this Agreement shall be construed to override the provisions of this Section 3.2. 

Section 4: Publication 

4.1    Principal Investigator shall be free to publish the data/results of the Study subject only to the provisions of
Section 8 regarding Company’s Proprietary Information. The Institution shall require Principal Investigator to furnish Company with a copy of any proposed publication prior to submission for publication, at least thirty (30) days
prior to submission for manuscripts and at least seven (7) days prior to submission for abstracts. Company shall be entitled to review such proposed publications solely for the purpose of identifying Company Proprietary Information, which shall
be removed from the publication upon Company’s request to the extent such deletion does not preclude the complete and accurate presentation and interpretation of the Study results; and to identify any patentable Inventions, which shall be
addressed as described below; and to provide any other comments Company desires to provide, provided that Principal Investigator shall have no obligation to address any such additional comments. At the expiration of such thirty (30) day or
seven (7) day period, Principal Investigator may proceed with submission for publication provided that any identified Company Proprietary Information has been removed; and provided further that upon notice by Company that Company reasonably
believes a patent application claiming an Invention (as defined in Section 5) should be filed prior to such publication, in Institution’s discretion such submission shall be delayed for up to an additional sixty (60) days or until any
patent application or applications have been filed, whichever shall first occur. In no event shall the submission of such publication of results be delayed for more than ninety (90) days for manuscripts and for more than sixty-seven
(67) days for abstracts from the date such proposed publication was provided to Company; at the end of said ninety (90) or sixty- seven (67) days, the Principal Investigator shall be free to publish such results as proposed. 

 4.2    Nothing herein shall be construed to restrict disclosure of
results by Institution and Principal Investigator as necessary for patient and public safety concerns, to prevent an immediate hazard to the safety, rights or welfare of patients or the public and/or for regulatory compliance. 

Section 5: Inventions/Intellectual Property 

5.1    Invention. It is expressly agreed that neither Company nor Institution transfers by operation of this Agreement to the other
party any patent right, copyright, or other proprietary right either party owns as of the Effective Date. Institution will promptly and fully disclose in writing to Company any inventions in the performance of the Study as outlined in the Protocol
(“Invention”). “Company Invention” means Invention that relate to the Study Drug. Institution will promptly and fully disclose in writing to Company, Company Invention. 

a. Option for Exclusive Commercialization License for Company Invention. Subject only to any non-exclusive license retained by the U.S. Government or any non-profit organization providing funding for the Study, Institution grants to Company an option to obtain an
exclusive, royalty-bearing and sublicensable license to Institution’s interests, if any, in any Company Invention conceived of within one (1) year of the Study Conclusion and Company’s receipt of the final study report or draft
manuscript, to use such Company Invention for research purposes and to make, use and sell (or otherwise commercialize) any such Company Invention or any products that are covered by patent rights that claim or that include any such Company
Invention. This option is to be exercised by written notice to Institution during said three month period and the negotiation, during the three (3) months next following such notice, of a license agreement containing license terms standard for
agreements between universities and industry including without limitation clauses providing for payment of reasonable royalties and other compensation to Institution, objective, time-limited due diligence provisions for the development,
commercialization and marketing of a product embodying the Invention and product liability indemnification and insurance requirements which are acceptable to Institution’s liability insurance carrier. In the absence of such notice by Company
and agreement on license terms, Institution may grant a license to such Patent Rights to any other party b. Non-Exclusive Licenses. Institution grants to Company the following rights which Company may
sublicense to its Invention and/or marketing collaborators: 
  

	 	(i)	 Improvements. A perpetual, non-exclusive, royalty-free
license to Institution’s interest in Invention which are “improvements” of the Study Drug(s). 

	 	(ii)	 New Uses. A perpetual, non-exclusive, royalty-free
license to Institution’s interest in Invention which are “new uses” of the Study Drug(s). 

 c. Patent
Applications. 
 (i) Company Invention. Any patent applications necessary to protect the interests of the parties in any Company
Invention made solely by Institution will be prepared, filed, and prosecuted by Institution. Any patent applications necessary to protect the interests of the parties in any Company Invention made jointly by Institution and Company or will be
prepared, filed and prosecuted by Company All patent costs pertaining to any patent rights filed by mutual agreement of Company and Institution, including preparation, filing, prosecution, issuance and maintenance costs, shall be borne by Company.

 5.2    All information given to Company by Institution in accordance with Section 5.1 will be held in confidence
by Company so long as such information remains unpublished or publicly undisclosed by Institution. 
 Section 6: Use of Name 

Except for disclosure by Institution of Company’s support for the Study in publications, for purposes of recruitment/consent of Study
subjects, and for purposes of meeting any applicable requirements for the registration of the Study or of Study results with a publicly accessible or other clinical trial registry, neither Party to this Agreement shall use the name of the other
Party or of any staff member, employee, student, or agent of the other Party or any adaptation, acronym or name by which the other Party is commonly known, in any advertising, promotional or sales literature or in any publicity without the prior
written approval of the Party or individual whose name is to be used. 
 Notwithstanding this, it is acknowledged that Company, as a
publicly-listed company, may be required to disclose the existence of this agreement in mandatory filings to regulatory bodies, including, without limitation, the Securities and Exchanges Commission, NASDAQ, and the Australian Securities Exchange.
Company shall make reasonable efforts to notify Institution in advance of any such disclosures wherever possible, and Institution shall have the right to request reasonable amendments or redactions to any such disclosures. 

Section 7: Audits, Study Records 

Any audits or on-site visits conducted by Company will be undertaken in conjunction with Institution,
at reasonable times and with reasonable prior notice, and pursuant to guidelines established by Institution in order to assure patient confidentiality. If Company gains access to any protected health information of a Study subject that is not
covered by the informed consent form, Company shall hold such information in the strictest confidence, shall not remove records containing such information from the Institution and, if inadvertently removed, shall return any records containing such
information to the Institution as soon as practicable. If in connection with the Study or performance of this Agreement Company and/or any of its agents, employees, officers or representatives come into contact with individually identifiable health
information relating to patients of Institution who are not Study subjects, Company agrees to, and agrees to ensure its agents, employees, officers or representatives agree to, maintain the strictest confidentiality of such information and not to
use it for any purpose. All subject/patient medical records shall remain the property of Institution. Each of Company and Institution shall retain records of the Study, including in Institution’s case either the original or a copy of all
volunteer consent forms, in conformance with federal regulations applicable to it. Institution shall also make such records available upon request for review by representatives of the U.S. Food and Drug Administration. Company acknowledges that
Company may not direct the manner in which Institution fulfills its obligations to permit inspection by governmental entities. It shall not be a breach of this Agreement for Institution to comply with the demands and requests of any governmental
entity in accordance with Institution’s judgment or to fail to inform and consult with Company before complying with any such demand or request. 

 Section 8: Confidential Information 

8.1    Provision of Confidential Information. It is anticipated that in the performance of the Study Principal
Investigator, Company and Institution may need to disclose to each other information, which is considered confidential and proprietary. A Party may provide Confidential Information Party (“Discloser”) to the other Party
(“Recipient”); provided that Company shall only disclose Company Confidential Information to persons who are designated in writing by the Principal Investigator as being authorized to receive Confidential Information (collectively with the
Principal investigator, the “Institution Personnel”). The rights and obligations of the Parties with respect to Confidential Information are as follows: 

8.2    Definition. For the purposes of this Agreement, “Confidential Information” refers to information
of any kind, other than data from or results of the Study, that satisfies all of the following: (i) such information is disclosed by Discloser to Recipient, (ii) such information by appropriate marking, is identified as confidential at the
time of disclosure, and (iii) the disclosure of such information is necessary for a Party to exercise its rights or perform its obligations under this Agreement. In the event that Confidential Information must be provided visually or orally,
obligations of confidence shall attach only to that information that is confirmed by Discloser in writing within ten (10) working days of provision as being confidential. 

8.3    Period of Restriction. For a period of five (5) years after the Study Conclusion of this Agreement,
Recipient agrees to use reasonable efforts, no less than the protection given its own confidential information, to use Confidential Information received from Discloser and accepted by Recipient only in accordance with this Section 8. 

8.4    Use of Confidential Information. Institution agrees and shall require each member of the Institution
Personnel to agree to use Company Confidential Information solely for the purposes of conducting the Study, obtaining any required review of the Study or its conduct, or ensuring proper medical treatment of any patient or subject. Company agrees and
shall require any of its employees with whom such information is shared to agree, to use Institution Confidential Information solely to exercise Company’s rights or perform Company’s obligations hereunder. Company acknowledges and agrees
that (i) Institution is an academic medical center in which the free exchange of information is actively encouraged among staff and researchers and (ii) Institution’s obligations with respect to Company Confidential Information under this
Section 8 (including subsections) shall apply only to disclosures thereof made to the applicable members of the Institution Personnel and not to disclosures thereof to any other person associated with Institution or any of its affiliates 

 8.5    Release of Confidential Information. Except as provided
herein, Recipient agrees to keep all Confidential Information confidential unless Discloser gives specific written consent for release 

8.6    Notice of Unauthorized Disclosure. Recipient shall notify Discloser of any disclosure not authorized
hereunder of which it becomes aware. In such situations, Recipient shall take reasonable steps to prevent any further disclosure or unauthorized use. 

8.7    Exclusions. No Recipient shall be required to treat any information as Confidential Information under this
Agreement in the event: 
  

	 	(i)	 it is publicly available prior to the date of the Agreement or becomes publicly available thereafter through no
wrongful act of any Recipient; 

  

	 	(ii)	 it was known to any Recipient prior to the date of disclosure or becomes known to any Recipient thereafter from
a third party having an apparent bona fide right to disclose the information; 

  

	 	(iii)	 it is disclosed by any Recipient in accordance with the terms of Discloser’s prior written approval;

  

	 	(iv)	 it is disclosed by Discloser without restriction on further disclosure; 

 

	 	(v)	 it is independently developed by any Recipient; 

 

	 	(vi)	 it is necessary to disclose for patient treatment, patient safety or to prevent imminent harm to the public or,

  

	 	(vii)	 any Recipient is obligated to produce it pursuant to a requirement of applicable law or an order of a court of
competent jurisdiction or a facially valid administrative, Congressional or other subpoena, provided that the Recipient subject to the requirement or order or subpoena (A) promptly notifies Discloser and (B) cooperates reasonably with
Discloser’s efforts to contest or limit the scope of such disclosure. 

 8.8    Each Party
reserves the right, in its sole discretion and without prior notice to any other Party, to disclose its own Confidential Information to any third party for any purpose. 

Section 9: Budget 

9.1    General. Company agrees to support this Study with a research budget and payment schedule attached hereto as
Exhibit B and incorporated by reference herein. Institution shall monitor expenditures, in accordance with its policies, to ensure that the funds provided by Company are spent in accordance with this Agreement and approved budgets.
Institution agrees to use the funding provided under this Agreement solely for the purposes of carrying out the Study. 

 9.2    Budget. Checks shall be made payable to “Dana
Farber/Partners CancerCare, Inc.” Federal Tax ID# 04-3320640, shall reference the name of the Principal Investigator, the Protocol number and shall be forwarded to: 

Dana-Farber/Cancer Institute 450 

Brookline Ave, BP317BP316 

Boston, MA 02215 Attn: James R. Huse 

9.3    Clinical Care Procedures. Company acknowledges that the budget for the Study has been negotiated in good
faith and that any items and services specified in the Study Protocol that are for the clinical care of the Study subject (specifically, conventional care items and services as well as items and services to detect or prevent complications) are
eligible for third party reimbursement. Company shall treat all patient specific billing information as individually identifiable health information subject to the HIPAA protections in Section 3.2. Further, Company shall treat all Institutional
billing and financial information as Institutional Confidential Information subject to the protections in Section 8. 

9.4    Compliance with Laws. The Parties shall comply with all applicable laws, rules and regulations, including
the federal Anti-Kickback Statute at 42 U.S.C. 1320a-7(b) and all applicable conditions of participation in governmental health care programs. In furtherance thereof, the Parties hereto agree as follows: 

(i) All services to be performed by Institution to or for the benefit of Company are and shall be as expressly set forth in this Agreement.

 (ii) The aggregate compensation payable to Institution pursuant to this Agreement is and shall be determined as specifically set forth in
this Agreement. 
 (iii) The rates of compensation for Institution’s services are and shall be consistent with the fair market value of
such services in the United States and have not been and shall not be determined in a manner which takes into account the volume or value of any referrals or business actually or potentially otherwise generated between Company and Institution or any
of Institution’s affiliates. 
 (iv) Nothing in this Agreement shall obligate Company or Institution to recommend or arrange for the
products or services offered by any Party, any affiliate thereof or any third party. 
 No Party or its affiliates shall request that any
other Party or its affiliates engage in any counseling or promotion of any business arrangement or other activity inconsistent with the requirements of applicable law. 

 (v) The services rendered by Institution shall be rendered solely to the extent reasonably
necessary to address areas of genuine clinical and research concern for which there is a legitimate need and purpose. 
 (vi) The decision by
Company to engage Institution to conduct the Study pursuant to this Agreement has been made by individuals qualified to evaluate the quality and integrity of Institution as a clinical trial site and without reference to the volume or value of any
referrals or business otherwise actually or potentially generated between or among Company, Institution, the Institution Personnel, or any of their respective affiliates. 

(vii) If any part of this Agreement is determined to violate, or to be likely to violate, federal, state, or local laws, rules, or regulations,
the Parties agree to negotiate in good faith all reasonably necessary revisions to this Agreement to cure the violation or reduce the likelihood of the violation. If the Parties are unable to agree to new or modified terms as required to bring the
entire Agreement into compliance, either Party may terminate this Agreement. 
 Section 10: Term and Termination 

10.1    Term. The term of this Agreement shall be from the Effective Date until completion of the Parties’
substantive obligations under the Agreement in the performance of the Study, unless earlier terminated in accordance with Section 10.2. 

10.2    Termination. 

(a)    Either Party hereto shall have the right to terminate the Study and this Agreement at any time upon thirty
(30) days prior written notice thereof to the other Party. Either Party may terminate the Study and this Agreement at any time upon thirty (30) days prior written notice thereof to the other Party in the event of a material breach of the
Agreement by the other Party, and except that either Party may terminate the Study and this Agreement immediately upon written notice to the other Party if necessary to protect the health, welfare or safety of any Study subject. 

(b)    If the Principal Investigator ceases to serve in such role during the term of the Agreement, Institution shall
promptly notify Company. Institution may name a substitute principal investigator (who shall thereafter be referred to as Principal Investigator for purposes of this Agreement), subject to the approval of Company, which approval may be withheld in
Company’s sole discretion. If the Parties fail to reach agreement with respect to continuation of the Study and the Agreement within ninety (90) days following the date on which Institution notifies Company that the original Principal
Investigator became unavailable, Company shall have the right to terminate the Study and this Agreement immediately upon written notice to Institution. 

10.3    Continuation of Enrolled Patients. The Parties agree that if, at the time either Party receives notice of
termination pursuant to this section, any patients are enrolled in the Study, and said patients shall complete the Study, at Company’s expense, if completion is in the best interest of said patients. 

10.4    Continuation of Grant. In the event of any termination other than a
for-cause termination by Company for Institution’s material breach, the amount of the research grant by Company to support the Study shall be appropriately prorated to allow Institution to recover
reasonable costs and noncancellable commitments incurred, including without limitation, termination salary costs of any Institution personnel released as a result of such termination. 

 10.5    Survival. The obligations of the Parties under Sections
1, 2, 3, 4, 5, 6.1, 7.1, 8, 9, 10.3, 10.4, 11, 13.2, and 13.4-13.7 shall survive any termination or expiration of this Agreement. 

Section 11: Subject Injury; Indemnification; and Insurance 

11.1    Subject Injury. 

(a) Company agrees to reimburse Institution for (or otherwise pay for) the costs of the care and treatment of any side effect, adverse
reaction, illness, or injury to a subject resulting from a defect in the Study Drug. 
 (b) Company’s subject injury commitment under
(a) above shall not apply to any side effect, adverse reaction, illness, or injury to the extent it directly results from: (i) the negligence or reckless or intentional misconduct of, or violation of law by, Institution, Principal
Investigator, or Institution’s personnel; or (ii) failure of Institution, Principal Investigator, or Institution’s personnel to adhere to the terms of the Protocol for the Study, provided, however, that emergency medical care shall
not be deemed a violation of the Protocol. 

 11.2    Indemnification. 

(a) Company will indemnify, defend and hold harmless, the Institution, its officers, agents, directors, trustees, subsidiaries, affiliates,
employees, students and members of its IRB, and their respective heirs, successors and assigns (collectively, “Institutional Indemnitees”) from and against any and all liability, damage, judgment, loss or expense (including reasonable
attorneys’ fees and costs) (“Liability”) that may be incurred by or imposed upon the Institutional Indemnitees or any of them in connection with any claim, suit, demand, action or judgment arising out of or relating to the following:
(i) the design, production, manufacture, labeling and/or shipment of the Study Drug; (ii) Company’s or Company’s affiliates, trustees, officers, professional staff, employees or agents (“Company Persons”) use, non-use, interpretation, disclosure or publication of any of the Study Data, results and/or any intellectual property that results from or arises out of the Study; and (iii) any negligence or willful misconduct
of Company or any Company Person 
 (b) Company’s indemnification under (a) above shall not apply to any liability, damage, loss
or expense to the extent that it is directly attributable to: (i) the negligence or reckless or intentional misconduct of, or violation of law by, the Indemnitees; or (ii) failure of the Indemnitees to adhere to the terms of the Protocol
for the Study, provided, however, that emergency medical care shall not be deemed a violation of the protocol. 
 (c) Company agrees, at its
own expense, to provide attorneys reasonably acceptable to Institution to defend against any actions brought or filed against any Party or individual indemnified hereunder with respect to the subject of the indemnity contained herein, whether or not
such actions are rightfully brought 
 11.3    Insurance 

(a) Company shall, at its sole cost and expense, procure and maintain policies of professional and general liability insurance in amounts not
less than Three Million Dollars ($3,000,000) per occurrence or claim and Five Million Dollars ($5,000,000) annual aggregate covering its obligations under this Agreement, including contractual liability coverage for its subject injury and
indemnification obligations. 
 (b) Company shall provide Institution at its request with written evidence of such insurance prior to the
commencement of the Study. Company shall provide Institution with written notice at least thirty (30) days prior to the cancellation, non-renewal or material change, in such insurance; if Company does not
obtain replacement insurance providing comparable coverage within such thirty (30) day period, Institution shall have the right to terminate this Agreement effective at the end of such thirty- (30) day period without notice of any
additional waiting periods. 

 Section 12: Notices 

12.1 Any written notices, reports, correspondences or other communications required under or pertaining to this Agreement shall be given by
prepaid, first class, registered or certified mail or by an express/overnight delivery service provided by a commercial carrier, properly addressed as follows: 

Institution: 
 Dana-Farber Cancer Institute
Research 
 Administration 450 Brookline Ave, 10 

BP319 Boston, MA 02215 Attn: 

Christopher Canova, JD (T) 617-632-2428 

ccanova1@partners.org 
 Company:
       Kazia Therapeutics Limited 
 L24, 300 Barangaroo Avenue, 

Sydney, NSW 2000 Australia 

Attn: Jeremy Simpson, PhD 
 (T)
+61 400 410 974 
 Jeremy.Simpson@kaziatherapeutics.com 

Section 13: Miscellaneous 

13.1    Amendment. The terms of this Agreement can be modified only by a writing, which is signed by authorized
representatives of Institution and Company. 
 13.2    Choice of Law; Jurisdiction and Venue. This Agreement
shall be governed by and construed and interpreted in accordance with the laws of the Commonwealth of Massachusetts. Each Party agrees to submit to the exclusive jurisdiction of the Superior Court for Suffolk County, Massachusetts, and the United
States District Court for the District of Massachusetts with respect to any claim, suit, or action in law or equity arising in any way out of this Agreement or the subject matter hereof. 

13.3    Assignment. Neither Party to this Agreement may assign its obligations hereunder without the prior written
consent of the other Party. 
 13.4    Entire Agreement. This Agreement, including any exhibits, attachments, and
other documents that are incorporated by reference herein, constitutes the entire understanding and agreement between the Parties, and supersedes and replaces all prior agreements, understandings, writings and discussions between the Parties with
respect to the subject matter of this Agreement. 

 13.5    Waiver. The failure of a Party in any instance to insist
upon the strict performance of the terms of this Agreement shall not be construed to be a waiver or relinquishment of any of the terms of the Agreement, whether at the time of the Party’s failure to insist upon strict performance or at any time
in the future, and such term(s) shall continue in full force and effect. 
 13.6    Severability. Each clause of
this Agreement is a distinct and severable clause and if any clause is deemed illegal, void, or unenforceable, the validity, legality, or enforceability of any other clause of this Agreement will not be affected thereby. 

13.7.    Titles. All the titles and headings contained in the Agreement are inserted only as a matter of
convenience and reference and do not define, limit, extend, or describe the scope of this Agreement or the intent of any of its provisions. 

13.8    Counterpart Signatures. This Agreement, and any subsequent amendment(s), may be executed in counterparts
and the counterparts, together, shall constitute a single Agreement and shall become binding when any one or more counterparts hereof, individually or taken together, bears the signature of each of the parties hereto. A facsimile or e-mail delivery of a “.pdf’ format data file of this Agreement signed by a party’s duly authorized representative shall be legal and binding on all parties. 

[SIGNATURE PAGE FOLLOWS] 

 IN WITNESS WHEREOF, the Parties hereto have executed this Agreement through their duly authorized
representatives as of the Effective Date written above. 
  

											
	KAZIA THERAPEUTICS LTD	  		 	DANA-FARBER/PARTNERS	  	
		  	DocuSigned by:	  		 	CANCERCARE, INC.	  	
						
	By:	  	 /s/ James Garner
	  		 	By:	  	 /s/ Christopher Canova
	  	
		  	(duly authorized signatory)	  		 		  	(duly authorized signatory)	  	
	Name:	  	James Garner	  		 	Name:	  	Christopher Canova
	Title:	  	Chief Executive Officer	  		 	Title:	  	Clinical Trials Research Associate
	Date:	  	October 20, 2018	  		 	Date:	  		  	
					
		  		  		 	READ AND ACKNOWLEDGED: PRINCIPAL INVESTIGATOR	  	
						
		  		  		 	By:	  	 /s/ Pablo Leone
	  	
		  		  		 	Date:	  	October 17, 2018	  	

 Clinical Trial Agreement 

 EXHIBIT A 

PROTOCOL 
 Final protocol to be appended.

 EXHIBIT B 

BUDGET AND PAYMENT SCHEDULE 
 Kazia
Therapeutics Limited will provide up to xx% of the total budget figure below (that is $). 
 Kazia will be invoiced on a quarterly basis as of contract
execution. 
 The funding for this study may be offset by independent grant support. This may be grant support of research organization alone of in
collaboration with Kazia. In the latter case, the distribution of funds will be agreed at the time of grant award. 
 A phase II trial of GDC-084 + trastuzumab in patients with HER2+ breast brain metastases 
  

													
		  				 	 	Company	 	  			
	Protocol No	  	 	TBD	 	 	 	Name	 	  	 	Kazia	 
	Duration of Study (months)	  	 	36	 	 	 	Overall Site	 	  	 	DFCI	 
	Number of Patients	  	 	47	 	 	 	DFCI PI	 	  	 	Pablo Leone	 
		  				 	 	RUC	 	  	 	RH34	 
		  	 	PI Initiated Trial	 	 	 	Site PI	 	  	 	Pablo Leone	 
				
	 BUDGET ITEMS
	  	Percent Effort	 	 	 	 	  	Study Costs	 
	 PERSONNEL:
	  				 				  			
	 Study Oversight and Management
	  	 		% 	 	$	                 	 	  	$	                 	 
	 Projects Manager
	  	 		% 	 	$	 	 	  	$	 	 
	 Clinical Research Coordinator
	  	 		% 	 	$	 	 	  	$	 	 
	 Data Manager(s)
	  	 		% 	 	$	 	 	  	$	 	 
	 Reg Coordinator
	  	 		% 	 	$	 	 	  	$	 	 
	 Research Nurse
	  	 		% 	 	$	 	 	  	$	 	 
				
	 TOTAL PERSONNEL
	  				 	$	 	 	  	$	 	 
				
	 OUTPATIENT CARE COSTS
	  				 				  			
	 Tests/Procedures, etc.
	  				 	$	 	 	  	$	 	 
				
	 TOTAL PATIENT CARE
	  				 	$	 	 	  	$	 	 
	 Clinical Research Sample Prep
	  	 	DFCI/MGH/Other	 	 	$	                 	 	  	$	                 	 
	 TOTAL CLINICAL RESEARCH SAMPLE PREP
	  				 	$	 	 	  	$	 	 
	 OTHER EXPENSES
	  				 				  			
	 Supplies
	  				 	$	 	 	  			
	 Shipping Costs
	  				 	$	 	 	  			
	 Shared Resources (e.g., MDLab)
	  				 	$	—  	 	  			
	 Storage fees
	  				 	$	 	 	  	$	 	 
	 Research Laboratory Component
	  				 	$	—  	 	  	$	—  	 
	 TOTAL OTHER EXPENSES
	  				 	$	 	 	  	$	 	 
	 TOTAL DIRECT COSTS:
	  				 	$	 	 	  	$	 	 
	 Indirect Costs @30% Total Direct Costs
	  				 	$	 	 	  	$	 	 
	 TOTAL COSTS PER PATIENT*
	  				 	$	 	 	  	$	 	 
	 *DFCI and MGH participating
	  				 				  			
	 IRB Protocol Review and Renewals
	  				 	$	 	 	  			
	 Pharmacy Fee ($2,500/site)
	  				 	$	 	 	  			
	 Administrative Start-up
	  				 	$	 	 	  			
	 DFHCC Administrative Fee
	  				 	$	 	 	  			
	 Close-out Fee
	  				 	$	 	 	  			
	 BioStats Fee
	  	 
	Covered by Spore
Grant	 
 	 				  			
	 STUDY TOTAL
	  				 	$	 	 	  			

 Responsibilities - Phase 2 Clinical Study 

GDC-0084 15mg Capsules 

Background & Scope: 
  

	 	(i)	 Institution plans to Sponsor a Phase 2 clinical study with GMP responsibilities as indicated below.

  

	 	(ii)	 Company will supply to Institution GMP manufactured and primary packed Study Drug (Investigational Medicinal
Product - IMP) for Phase 2 clinical trial use in the US under Dana-Farber Protocol. Company GMP responsibilities as indicated below. 

  

							
	 #
	  	 Responsibility
	  	Company	  	Institution
	1	  	IMP: Supply of GMP manufactured and primary packed (unlabeled) Study Drug (GDC-0084 15mg capsules, 35 capsules per bottle) in the agreed strengths (active only, no placebo), with
supporting GMP documentation (e.g. manufacturers CoAs)	  	X	  	
				
	2	  	IMP: Each bottle of Study Drug supplied will be identified (e.g. ink-jet printed) with unique lot number to prevent risk of mix-up	  	X	  	
				
	3	  	Retest Date & Storage Conditions: Provision of retest date(s) and storage conditions for the Study Drug supplied	  	X	  	
				
	4	  	IMP Ordering: Requests for Study Drug shipment will be provided to Company in writing	  		  	X
				
	5	  	Shipping: Will ship Study Drug to Institution accompanied by relevant paperwork (e.g. packing list)	  	X	  	
				
	6	  	Receipt & Labelling: Receive, store and label Study Drug for clinical trial use	  		  	X
				
	7	  	Release of IMP: responsibility for release of labelled Study Drug for Phase 2 clinical trial use in US	  		  	X
				
	8	  	Product Defects / Product Complaints: will promptly notify the other party if a Product Quality Defect is observed or reported (e.g. damaged Study Drug capsules or primary packaging)	  	X	  	X
				
	9	  	Product Recall: Company are overall responsible for any product recall decision. Company will notify Institution in the event of a Product Recall and both parties will work together as may be required to coordinate both
the Recall activities and notifications to the relevant regulatory authorities as may be applicable [Note: Product Recall may also be referred to as “stock recovery” in certain territories (e.g. US) as the Sponsor exerts direct control
over the drug].	  	X	  	X
				
	10	  	 Returns & Destruction: Responsibility for any returns and destruction rests with [Note: the process for
destruction to be agreed with
 Company]
	  		  	X

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}]]